Dermatological toxicities induced by T-cell-redirecting G protein-coupled receptor family C class 5 member D bispecific antibody talquetamab

To the Editor: Talquetamab is a first-in-class monoclonal antibody targeting both the G protein-coupled receptor family C class 5 member D (GPRC5D) and T-cell receptor CD3. Talquetamab redirects T cells to mediate killing of GPRC5D-expressing myeloma cells.1 The use of this bispecific T-cell engager has been associated with promising results in phase I and II clinical trials for relapsed or refractory multiple myeloma.2